A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
A phase 3 trial of Tucidinostat (chidamide) and XNW5004 in peripheral T-cell lymphomas, run by Evopoint Biosciences Inc., now recruiting.
Overview
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma is a phase 3 interventional study registered as NCT06776952 by Evopoint Biosciences Inc., with 120 participants planned, started 2025-04-10 and due to reach its primary completion in 2028-01. Interventions recorded: XNW5004 ; Chidamide placebo and XNW5004 placebo; Chidamide.
Similar pages
not linked directly; found by shared links- TrialChidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialClinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Shares Evopoint Biosciences and the tag pipeline.
- TrialStudy of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
Shares Evopoint Biosciences and the tag pipeline.
- TrialStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Shares Evopoint Biosciences and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.